New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD

Abnormalities in bone and mineral metabolism begin to develop in the early stage of CKD. Serum phosphorus, calcium, PTH, and alkaline phosphatase are recommended to be measured from CKD stage 3, and it is suggested that these markers are maintained within the reference ranges of each facility. The m...

Full description

Saved in:
Bibliographic Details
Published inClinical calcium Vol. 24; no. 12; p. 1845
Main Author Ando, Ryoichi
Format Journal Article
LanguageJapanese
Published Japan 01.12.2014
Subjects
Bone Diseases, Metabolic - drug therapy
Bone Diseases, Metabolic - etiology
Bone Diseases, Metabolic - metabolism
Calcium - metabolism
Fibroblast Growth Factors - metabolism
Humans
Parathyroid Hormone - metabolism
Potassium - metabolism
Renal Dialysis
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Abnormalities in bone and mineral metabolism begin to develop in the early stage of CKD. Serum phosphorus, calcium, PTH, and alkaline phosphatase are recommended to be measured from CKD stage 3, and it is suggested that these markers are maintained within the reference ranges of each facility. The management of phosphorus is essential and is composed of phosphorus restriction and phosphate binders. Small amount of VDRA suppresses PTH for secondary hyperparathyroidism and is expected to reduce mortality and proteinuria. The effects of the intervention to reduce the phosphorus load before hyperphosphatemia is manifested need to be investigated.
ISSN:0917-5857